Societal CDMO, Inc. (SCTL)
| Market Cap | 43.38M |
| Revenue (ttm) | 79.75M |
| Net Income (ttm) | -8.87M |
| Shares Out | 56.35M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | 18.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,559 |
| Open | 0.795 |
| Previous Close | 0.790 |
| Day's Range | 0.773 - 0.812 |
| 52-Week Range | 0.773 - 2.670 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 5.10 (+562.4%) |
| Earnings Date | May 11, 2022 |
About SCTL
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logis...
Financial Performance
In 2021, Societal CDMO's revenue was $75.36 million, an increase of 13.33% compared to the previous year's $66.50 million. Losses were -$11.37 million, -58.66% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for SCTL stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 562.42% from the latest price.
News
Societal to Participate in Upcoming Investor Conferences
SAN DIEGO and GAINESVILLE, Ga., May 19, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated t...
Societal CDMO Reports First Quarter 2022 Financial Results
Recorded Q1 Revenue of $21 Million; A 26% Increase Compared to Prior Year Period
Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA® in Europe
Agreement Establishes Societal as Exclusive Supplier in Europe Through 2023 Agreement Establishes Societal as Exclusive Supplier in Europe Through 2023
Societal CDMO to Report Financial Results for First Quarter 2022 on May 11, 2022
Conference Call and Webcast Scheduled for Wednesday, May 11, 2022, at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Wednesday, May 11, 2022, at 4:30 p.m. Eastern
Societal CDMO Secures Manufacturing and Packaging Task Order Award from National Cancer Institute (NCI)
SAN DIEGO and GAINESVILLE, Ga., April 27, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving co...
Down 25.9% in 4 Weeks, Here's Why Societal CDMO (SCTL) Looks Ripe for a Turnaround
Societal CDMO (SCTL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimat...
Societal CDMO Reports Inducement Grants for New Staff
SAN DIEGO and GAINESVILLE, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving co...
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society
Recro Reports Fourth Quarter and Year End 2021 Financial Results
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of To...
SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex for...
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex form...
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
Recro Reports Third Quarter 2021 Financial Results
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
Agreement Establishes Recro as Commercial Supplier for Otsuka
Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic
Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The...
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Sp...
New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIH New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturi...
Recro Reports Inducement Grants For New Staff
Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.
Recro Signs Renewable Energy Agreement With Georgia Power
Investment in Renewable Energy Credits Represents Key Component of Company's Ongoing Environmental Sustainability Program Investment in Renewable Energy Credits Represents Key Component of Company's Ong...
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufa...